death worldwide every year. In addition, the treatment is becoming
more and more difficult because of emergence of drug-resistant
malaria. Artemisinin combination therapy (ACT) has been useful
over past decades [1], but the recent emergence of ACT resistance
[2] provides strong motivation to discover new potential antimalarial
drugs. Parasite growth and ability to maintains stress is linked
to the down-stream signaling and ribosome biogenesis [3]. RIO like
kinase, RIO-1 (PFL1490w) and RIO-2 kinase (PFD0975w) are present
in the malaria kinome with uncharacterized function (www.
plasmodb.org). Structural characterization of PFD0975w, the RIO-
2 kinase of Plasmodium Falciparum (PfRIO-2 kinase) indicates Nterminal
DNA binding winged helix domain (1e84), a linker region
(85e147) and C-terminal kinase domain (148e275). It has a well
defined ATP binding pocket and is significantly different than the
human RIO-2 kinase [4]. Further, the absence of activation loop and
distinguished structural features of PfRIO-2 kinase provides an
opportunity to explore it as a new drug target [4]. Recently, naturally
occurring bioactive molecules and selected heterocycles were
screened against PfRIO-2 kinase, which allow us to delineate
pharmacological points required for inhibitor development against
PfRIO-2 kinase [5,6].
death worldwide every year. In addition, the treatment is becoming
more and more difficult because of emergence of drug-resistant
malaria. Artemisinin combination therapy (ACT) has been useful
over past decades [1], but the recent emergence of ACT resistance
[2] provides strong motivation to discover new potential antimalarial
drugs. Parasite growth and ability to maintains stress is linked
to the down-stream signaling and ribosome biogenesis [3]. RIO like
kinase, RIO-1 (PFL1490w) and RIO-2 kinase (PFD0975w) are present
in the malaria kinome with uncharacterized function (www.
plasmodb.org). Structural characterization of PFD0975w, the RIO-
2 kinase of Plasmodium Falciparum (PfRIO-2 kinase) indicates Nterminal
DNA binding winged helix domain (1e84), a linker region
(85e147) and C-terminal kinase domain (148e275). It has a well
defined ATP binding pocket and is significantly different than the
human RIO-2 kinase [4]. Further, the absence of activation loop and
distinguished structural features of PfRIO-2 kinase provides an
opportunity to explore it as a new drug target [4]. Recently, naturally
occurring bioactive molecules and selected heterocycles were
ร่มกับ pfrio-2 kinase ซึ่งช่วยให้เราสามารถวาดรูป
จุดทางเภสัชวิทยาที่จำเป็นสำหรับการพัฒนาตัวยับยั้งต่อ
pfrio-2 ไคเนส [ 5 , 6 ]
การแปล กรุณารอสักครู่..
